Affordable Access

Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients.

Authors
  • Grigorescu, A C
  • Bala, C
Type
Published Article
Journal
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Publication Date
Jan 01, 2013
Volume
18
Issue
1
Pages
188–194
Identifiers
PMID: 23613405
Source
Medline
License
Unknown

Abstract

Taking into account similar published clinical studies we conclude that gemcitabine plus erlotinib achieve superior response rate and comparable overall survival with acceptable toxicity compared to monochemotherapy with gemcitabine. This combination represents a treatment option for patients with advanced NSCLC and ECOG PS 2.

Report this publication

Statistics

Seen <100 times